Haystack MRD® receives New York State approval
We’re proud to be part of the 2026 American Society of Clinical Oncology (ASCO®) annual meeting, where we’ll present 2 posters featuring new clinical data using Haystack technology.
We can’t wait to introduce you to our new cast of characters who will show you how Haystack MRD provides confidence in MRD test results.
Learn more about the conference here
Meet our clinical and executive teams and learn how circulating tumor DNA (ctDNA) testing with Haystack MRD® can help you to:
And while you’re there, you’ll meet our new face of Confidence! Be sure to visit our booth to see what we have in store.
We are proud to collaborate with clinical researchers to present 2 research posters at ASCO this year featuring Haystack technology:
Abstract: 4101
Poster number: 84
Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Session time and date: May 30, 9:00 AM-12:00 PM
In this study, a tumor-informed, whole-genome sequencing (WGS) platform was used to detect peritoneal tumor DNA (ptDNA) in patients with gastroesophageal cancers. The results showed that ptDNA accurately diagnosed peritoneal metastasis in this patient cohort, as validated in 10 true negative and 12 true positive patients at a median follow-up time of 17 months. In addition, ptDNA predicted peritoneal recurrence and overall survival outcomes, suggesting the potential for ptDNA to help personalize treatment decisions. Additional data using Haystack MRD to detect ctDNA will be presented at the meeting.
Abstract: 6075
Poster number: 532
Session: Head and Neck Cancer
Session time and date: May 30, 1:30 PM-4:30 PM
This study compared circulating tumor DNA (ctDNA) and circulating human papillomavirus DNA (ctHPV-DNA) for monitoring patients with HPV-driven oropharyngeal cancers. The goal of the study was to learn whether ctDNA testing could better assess treatment response, help guide management, and detect minimal residual disease (MRD) in these patients. The results showed that the 2 tests were highly consistent in detecting disease, but with distinct kinesthetics for clearance. In patients undergoing treatment, ctDNA cleared several weeks to months earlier than ctHPV. These findings suggest that ctDNA may provide an earlier window into treatment response than ctHPV in patients with HPV-driven oropharyngeal cancers. Further research is ongoing to determine how these 2 tests can be used together for management of HPV-driven oropharyngeal cancers.
Haystack MRD is a tumor-informed test for detecting ctDNA in solid tumor settings. Superb sensitivity and specificity translate to better MRD detection for greater confidence when making key clinical decisions.
Haystack MRD was designed specifically for ultrasensitive ctDNA detection when testing for residual or recurrent disease. Better sensitivity helps ensure patients are more likely to receive the right treatment at the right time, which can significantly improve outcomes and quality of life for patients who have been diagnosed with cancer.
From early detection screening to diagnosis, monitoring, and beyond, Quest offers routine to advanced testing along the cancer care continuum. Experience the efficiency of working with a single lab to improve the quality and speed of cancer care.
Para solicitar ayuda financiera, complete la solicitud y firme la autocertificación.
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social:
Social: